Switch theme
Sign up to access all valuation multiples
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo’s pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
2011
23
LTM Revenue $0.3M
Last FY EBITDA -$68.3M
-$81.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Avalo Therapeutics has a last 12-month revenue (LTM) of $0.3M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Avalo Therapeutics achieved revenue of $0.4M and an EBITDA of -$68.3M.
Avalo Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Avalo Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $0.3M | XXX | $0.4M | XXX | XXX | XXX |
| Gross Profit | $31K | XXX | $0.8M | XXX | XXX | XXX |
| Gross Margin | 12% | XXX | 183% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$68.3M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -15497% | XXX | XXX | XXX |
| EBIT | -$65.0M | XXX | -$68.5M | XXX | XXX | XXX |
| EBIT Margin | -25135% | XXX | -15536% | XXX | XXX | XXX |
| Net Profit | -$45.1M | XXX | -$35.1M | XXX | XXX | XXX |
| Net Margin | -17442% | XXX | -7966% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Avalo Therapeutics's stock price is $4.
Avalo Therapeutics has current market cap of $43.2M, and EV of -$81.0M.
See Avalo Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$81.0M | $43.2M | XXX | XXX | XXX | XXX | $-14.28 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Avalo Therapeutics has market cap of $43.2M and EV of -$81.0M.
Avalo Therapeutics's trades at -183.8x EV/Revenue multiple, and 1.2x EV/EBITDA.
Equity research analysts estimate Avalo Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Avalo Therapeutics has a P/E ratio of -1.0x.
See valuation multiples for Avalo Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $43.2M | XXX | $43.2M | XXX | XXX | XXX |
| EV (current) | -$81.0M | XXX | -$81.0M | XXX | XXX | XXX |
| EV/Revenue | -313.4x | XXX | -183.8x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 1.2x | XXX | XXX | XXX |
| EV/EBIT | 1.2x | XXX | 1.2x | XXX | XXX | XXX |
| EV/Gross Profit | -2641.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.0x | XXX | -1.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 1.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAvalo Therapeutics's revenue per employee in the last FY averaged $19K, while opex per employee averaged $3.0M for the same period.
Avalo Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Avalo Therapeutics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Avalo Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -15497% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $19K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $3.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 179% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 11809% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 15719% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Avalo Therapeutics acquired XXX companies to date.
Last acquisition by Avalo Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Avalo Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Avalo Therapeutics founded? | Avalo Therapeutics was founded in 2011. |
| Where is Avalo Therapeutics headquartered? | Avalo Therapeutics is headquartered in United States of America. |
| How many employees does Avalo Therapeutics have? | As of today, Avalo Therapeutics has 23 employees. |
| Who is the CEO of Avalo Therapeutics? | Avalo Therapeutics's CEO is Dr. Garry A. Neil, M.D.. |
| Is Avalo Therapeutics publicy listed? | Yes, Avalo Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Avalo Therapeutics? | Avalo Therapeutics trades under AVTX ticker. |
| When did Avalo Therapeutics go public? | Avalo Therapeutics went public in 2015. |
| Who are competitors of Avalo Therapeutics? | Similar companies to Avalo Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Avalo Therapeutics? | Avalo Therapeutics's current market cap is $43.2M |
| What is the current revenue of Avalo Therapeutics? | Avalo Therapeutics's last 12 months revenue is $0.3M. |
| What is the current EV/Revenue multiple of Avalo Therapeutics? | Current revenue multiple of Avalo Therapeutics is -313.4x. |
| Is Avalo Therapeutics profitable? | Yes, Avalo Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
